PartnershipMay 6, 2026, 07:03 AM
Tonix Pharma Secures GPO Deal for TONMYA, Covering 35M Lives
AI Summary
Tonix Pharmaceuticals announced an agreement with a leading group purchasing organization (GPO) effective May 1, 2026, significantly expanding access to TONMYA® (cyclobenzaprine HCl sublingual tablets). This partnership provides coverage for approximately 35 million U.S. commercial lives, representing about 20% of the total commercial market. TONMYA, which commercially launched in November 2025 and was FDA-approved in August 2025, is the first new treatment for fibromyalgia in over 15 years. The company also noted existing Medicaid coverage in 38 states for approximately 55 million lives and plans to pursue additional coverage.
Key Highlights
- Tonix Pharmaceuticals secured a GPO agreement for TONMYA, covering approximately 35 million U.S. commercial lives.
- The agreement represents about 20% of the roughly 177 million commercial lives in the U.S.
- TONMYA commercially launched in November 2025 as the first new FDA-approved fibromyalgia treatment in over 15 years.
- TONMYA is covered under Medicaid in 38 states, reaching approximately 55 million lives (73% of total Medicaid lives).
- TONMYA's patents are expected to provide U.S. market exclusivity until 2034/2035.
- Fibromyalgia affects more than 10 million adults in the U.S.
- 85% of first-line fibromyalgia treatments fail due to efficacy and tolerability issues.